Xintela AB (publ) (STO:XINT)
0.1410
+0.0010 (0.71%)
Nov 20, 2026, 5:25 PM CET
Xintela AB Earnings Call Transcripts
Fiscal Year 2025
-
XSTEM demonstrated safety and sustained efficacy in osteoarthritis patients, with the highest dose halting cartilage degradation and improving bone structure over two years. The platform's unique MSC selection and in-house GMP facility support expansion into new indications and commercial partnerships.